Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1979 Sep 22;2(6192):700–703. doi: 10.1136/bmj.2.6192.700

Effects of bromocriptine on pituitary tumour size.

A M McGregor, M F Scanlon, R Hall, K Hall
PMCID: PMC1596246  PMID: 509071

Abstract

In a prospective study designed to assess the influence of bromocriptine on pituitary tumour size 12 patients with pituitary tumours, eight of whom had suprasellar extensions, were treated for three months with 20 mg of bromocriptine daily after a gradual increase to this dose. The group comprised eight women and four men, five with prolactin-secreting adenomas, four with acromegaly, two with functionless adenomas, and one with Nelson's syndrome. All five patients with prolactin-secreting adenomas showed a reduction in pituitary tumour size as assessed by computerised tomography and metrizamide cisternography accompanied by a fall in prolactin concentrations and clinical and biochemical improvement in their hypopituitarism. One patient in this group had a visual-field defect before treatment, and this resolved. There was no radiological evidence of reduction in tumour size in the remaining seven patients, though this might refect the fairly short duration of treatment, particularly in view of the ancillary evidence of clinical, biochemical, and visual-field improvement in some of the patients. These results emphasise the potential value of bromocriptine in treating patients with large prolactinomas or recurrences of such tumours after previous chiasmal decompression and conventional external megavoltage irradiation on the pituitary.

Full text

PDF
700

Images in this article

702p702-a
on p.702

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carter J. N., Tyson J. E., Tolis G., Van Vliet S., Faiman C., Friesen H. G. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med. 1978 Oct 19;299(16):847–852. doi: 10.1056/NEJM197810192991602. [DOI] [PubMed] [Google Scholar]
  2. Chang R. J., Keye W. R., Jr, Young J. R., Wilson C. B., Jaffe R. B. Detection, evaluation, and treatment of pituitary microadenomas in patients with galactorrhea and amenorrhea. Am J Obstet Gynecol. 1977 Jun 15;128(4):356–363. doi: 10.1016/0002-9378(77)90553-1. [DOI] [PubMed] [Google Scholar]
  3. Corrodi H., Fuxe K., Hökfelt T., Lidbrink P., Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol. 1973 May;25(5):409–412. doi: 10.1111/j.2042-7158.1973.tb10037.x. [DOI] [PubMed] [Google Scholar]
  4. Drayer B. P., Rosenbaum A. E., Kennerdell J. S., Robinson A. G., Bank W. O., Deeb Z. L. Computed tomographic diagnosis of suprasellar masses by intrathecal enhancement. Radiology. 1977 May;123(2):339–344. doi: 10.1148/123.2.339. [DOI] [PubMed] [Google Scholar]
  5. Evered D. C., Vice P. A., Green E., Appleton D. Assessment of thyroid hormone assays. J Clin Pathol. 1976 Dec;29(12):1054–1059. doi: 10.1136/jcp.29.12.1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ezrin C., Kovacs K., Horvath E. Hyperprolactinemia. Morphologic and clinical considerations. Med Clin North Am. 1978 Mar;62(2):393–408. doi: 10.1016/s0025-7125(16)31814-4. [DOI] [PubMed] [Google Scholar]
  7. Franks S., Nabarro J. D. Prevalence and presentation of hyperprolactinaemia in patients with "functionless" pituitary tumours. Lancet. 1977 Apr 9;1(8015):778–780. doi: 10.1016/s0140-6736(77)92959-2. [DOI] [PubMed] [Google Scholar]
  8. George S. R., Burrow G. N., Zinman B., Ezrin C. Regression of pituitary tumors, a possible effect of bromergocryptine. Am J Med. 1979 Apr;66(4):697–702. doi: 10.1016/0002-9343(79)91187-2. [DOI] [PubMed] [Google Scholar]
  9. Gross C. E., Binet E. F., Esguerra J. V. Metrizamide cisternography in the evaluation of pituitary adenomas and the empty sella syndrome. J Neurosurg. 1979 Apr;50(4):472–476. doi: 10.3171/jns.1979.50.4.0472. [DOI] [PubMed] [Google Scholar]
  10. Gómez F., Reyes F. I., Faiman C. Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med. 1977 May;62(5):648–660. doi: 10.1016/0002-9343(77)90866-x. [DOI] [PubMed] [Google Scholar]
  11. Hall R., Ormston B. J., Besser G. M., Cryer R. J. The thyrotrophin-releasing hormone test in diseases of the pituitary and hypothalamus. Lancet. 1972 Apr 8;1(7754):759–763. doi: 10.1016/s0140-6736(72)90518-1. [DOI] [PubMed] [Google Scholar]
  12. Hall R. The immunoassay of thyroid-stimulating hormone and its clinical applications. Clin Endocrinol (Oxf) 1972 Jan;1(1):115–125. doi: 10.1111/j.1365-2265.1972.tb00383.x. [DOI] [PubMed] [Google Scholar]
  13. Hwang P., Guyda H., Friesen H. A radioimmunoassay for human prolactin. Proc Natl Acad Sci U S A. 1971 Aug;68(8):1902–1906. doi: 10.1073/pnas.68.8.1902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jaquet P., Grisoli F., Guibout M., Lissitzky J. C., Carayon P. Prolactin secreting tumors. Endocrine status before and after surgery in 33 women. J Clin Endocrinol Metab. 1978 Mar;46(3):459–466. doi: 10.1210/jcem-46-3-459. [DOI] [PubMed] [Google Scholar]
  15. Kleinberg D. L., Noel G. L., Frantz A. G. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med. 1977 Mar 17;296(11):589–600. doi: 10.1056/NEJM197703172961103. [DOI] [PubMed] [Google Scholar]
  16. Lamberts S. W., Birkenhäger J. C. Bromocriptine in Nelson's syndrome and Cushing's disease. Lancet. 1976 Oct 9;2(7989):811–811. doi: 10.1016/s0140-6736(76)90656-5. [DOI] [PubMed] [Google Scholar]
  17. Landolt A. M., Wüthrich R., Fellmann H. Regression of pituitary prolactinoma after treatment with bromocriptine. Lancet. 1979 May 19;1(8125):1082–1083. doi: 10.1016/s0140-6736(79)92976-3. [DOI] [PubMed] [Google Scholar]
  18. MATTINGLY D. A simple fluorimetric method for the estimation of free 11-hydroxycorticoids in human plasma. J Clin Pathol. 1962 Jul;15:374–379. doi: 10.1136/jcp.15.4.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nillius S. J., Bergh T., Lundberg P. O., Stahle J., Wide L. Regression of a prolactin-secreting pituitary tumor during long-term treatment with bromocriptine. Fertil Steril. 1978 Dec;30(6):710–712. doi: 10.1016/s0015-0282(16)43702-7. [DOI] [PubMed] [Google Scholar]
  20. O'Mullane N., Walker B., Jefferson J., Hipkin L., Diver M., Davis C. Lack of effect of bromocriptine on ACTH levels in patients with bilateral adrenalectomy for pituitary-dependent Cushing's syndrome. J Endocrinol Invest. 1978 Oct;1(4):355–357. doi: 10.1007/BF03350982. [DOI] [PubMed] [Google Scholar]
  21. Pawlikowski M., Kunert-Radek J., Stepień H. Direct antiproliferative effect of dopamine agonists on the anterior pituitary gland in organ culture. J Endocrinol. 1978 Nov;79(2):245–246. doi: 10.1677/joe.0.0790245. [DOI] [PubMed] [Google Scholar]
  22. Quadri S. K., Lu K. H., Meites J. Ergot-induced inhibition of pituitary tumor growth in rats. Science. 1972 Apr 28;176(4033):417–418. doi: 10.1126/science.176.4033.417. [DOI] [PubMed] [Google Scholar]
  23. Reichlin S. The prolactinoma problem. N Engl J Med. 1979 Feb 8;300(6):313–315. doi: 10.1056/NEJM197902083000612. [DOI] [PubMed] [Google Scholar]
  24. Reuter A. M., Kennes F., Gevaert Y., Franchimont P. Homologous radioimmunoassay for human prolactin. Int J Nucl Med Biol. 1976 Jan;3(1):21–28. doi: 10.1016/0047-0740(76)90005-x. [DOI] [PubMed] [Google Scholar]
  25. Shaw R. W., Butt W. R., London D. R., Marshall J. C. Variation in response to synthetic luteinizing hormone--releasing hormone (LH-RH) at different phases of the same menstrual cycle in normal women. J Obstet Gynaecol Br Commonw. 1974 Aug;81(8):632–639. doi: 10.1111/j.1471-0528.1974.tb00530.x. [DOI] [PubMed] [Google Scholar]
  26. Thorner M. O., Besser G. M., Jones A., Dacie J., Jones A. E. Bromocriptine treatment of female infertility: report of 13 pregnancies. Br Med J. 1975 Dec 20;4(5998):694–697. doi: 10.1136/bmj.4.5998.694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wass J. A., Moult P. J., Thorner M. O., Dacie J. E., Charlesworth M., Jones A. E., Besser G. M. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet. 1979 Jul 14;2(8133):66–69. doi: 10.1016/s0140-6736(79)90120-x. [DOI] [PubMed] [Google Scholar]
  28. Wass J. A., Thorner M. O., Morris D. V., Rees L. H., Mason A. S., Jones A. E., Besser G. M. Long-term treatment of acromegaly with bromocriptine. Br Med J. 1977 Apr 2;1(6065):875–878. doi: 10.1136/bmj.1.6065.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Watson M. J., Fleetwood J. A. A reliable method for the specific determination of testosterone in plasma. Clin Chim Acta. 1974 Dec 2;57(2):135–141. doi: 10.1016/0009-8981(74)90421-5. [DOI] [PubMed] [Google Scholar]
  30. Werder K. v., Fahlbusch R., Landgraf R., Pickardt C. R., Rjosk H. K., Scriba P. C. Treatment of patients with prolactinomas. J Endocrinol Invest. 1978 Jan;1(1):47–58. doi: 10.1007/BF03346770. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES